It is the first medicine for hemophilia A that can be subcutaneously injected, like a shot under the skin, similar to the way ...

The treatment landscape for hemophilia with an inhibitor has changed drastically in recent years, columnist Cazandra Campos-MacDonald says.

Hemlibra (emicizumab), which can be given through outpatient care every few weeks; and drugs still in clinical trials such as fitusiran. There are two types of hemophilia A: hereditary and acquired.

Hemlibra (emicizumab) is already approved in the EU for haemophilia A patients with inhibitors, and the latest approval means Roche’s drug covers the whole disease population in Europe.

an antithrombin-targeting agent in development as a treatment for haemophilia A and B with as few as six injections per year, making it a potential rival to Roche's big-selling therapy Hemlibra ...

In contrast, Roche’s hemophilia A antibody drug Hemlibra booked 4.5 billion Swiss francs ($5 billion) in global revenue, good for 12% growth year over year. Pfizer got Beqvez in 2014 from Spark ...

New treatments have changed the face of managing hemophilia with an inhibitor, columnist Cazandra Campos-MacDonald writes.